Irritable Bowel Syndrome Pipeline and Clinical Trials Assessment (2023) | Companies- Arena Pharmaceuticals, 4D Pharma, OrphoMed, Boston Pharmaceuticals, RedHill Biopharma Limited, Takeda, and Others

DelveInsight's, "Irritable Bowel Syndrome Pipeline Insight, 2023," report provides comprehensive insights about 24+ companies and 24+ pipeline drugs in Irritable Bowel Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Irritable Bowel Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

For Irritable Bowel Syndrome Emerging drugs, the Irritable Bowel Syndrome pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Irritable Bowel Syndrome pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies. In the Irritable Bowel Syndrome Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Irritable Bowel Syndrome clinical trials studies, Irritable Bowel Syndrome NDA approvals (if any), and product development activities comprising the technology, Irritable Bowel Syndrome collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

To explore more information on the latest breakthroughs in the Irritable Bowel Syndrome Pipeline treatment landscape of the report, click here @ Irritable Bowel Syndrome Pipeline Outlook- https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key takeaways from the Irritable Bowel Syndrome Pipeline Report
• DelveInsight's irritable bowel syndrome pipeline report depicts a robust space with 24+ companies and 24+ pipeline drugs for irritable bowel syndrome treatment.
• The leading Irritable Bowel Syndrome Companies in the working include Arena Pharmaceuticals, 4D Pharma, OrphoMed, Boston Pharmaceuticals, RedHill Biopharma Limited, Takeda, Cosmo Technologies, CinRx Pharma, Rottapharm, Synthetic Biologics, Biomica, Metacrine, MGC Pharma, Napo Pharmaceuticals, Novome Biotechnologies, Renexxion, Sentia Medical Sciences, Serentrix LLC, Vitality Biopharma, and others.
• Promising Irritable Bowel Syndrome Pipeline Therapies in the various stages of development includes Olorinab, Blautix, ORP-101, BOS-589, BEKINDA, Rifamycin controlled-release, CIN 103, Crofelemer, RQ-00310941, AAT 730, and others.
• In October 2022, Intrinsic Medicine and Phoenix Biotech Acquisition Corp. announced they have entered into a definitive business combination agreement.
• In September 2022, Novome Biotechnologies, Inc., a biotechnology company engineering first-in-class, living medicines for chronic diseases, announced the closing of a $43.5 million Series B financing.

Irritable Bowel Syndrome Overview
Irritable bowel syndrome (IBS) is a group of symptoms that occur together, including repeated pain in your abdomen and changes in your bowel movements, which may be diarrhea, constipation, or both. With IBS, you have these symptoms without any visible signs of damage or disease in your digestive tract.

For further information, refer to the detailed Irritable Bowel Syndrome Unmet Needs, Irritable Bowel Syndrome Market Drivers, and Irritable Bowel Syndrome Market Barriers, click here for Irritable Bowel Syndrome Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Irritable Bowel Syndrome Emerging Drugs Profile
• ORP-101: OrphoMed
• Blautix: 4D Pharma

Irritable Bowel Syndrome Pipeline Therapeutics Assessment
There are approx. 24+ key companies which are developing the therapies for Irritable bowel syndrome. The companies which have their Irritable bowel syndrome drug candidates in the most advanced stage, i.e. phase II include OrphoMed.

Request a sample and discover the recent advances in Irritable Bowel Syndrome Ongoing Clinical Trial Analysis and Medications, click here @ Irritable Bowel Syndrome Treatment Landscape-https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Irritable Bowel Syndrome Pipeline Therapeutic Assessment
• Irritable Bowel Syndrome Assessment by Product Type
• Irritable Bowel Syndrome Assessment by Stage and Product Type
• Irritable Bowel Syndrome Assessment by Route of Administration
• Irritable Bowel Syndrome Assessment by Stage and Route of Administration
• Irritable Bowel Syndrome Assessment by Molecule Type
• Irritable Bowel Syndrome Assessment by Stage and Molecule Type

Some of the Companies in the Irritable Bowel Syndrome Therapeutics Market include-
Arena Pharmaceuticals, 4D Pharma, OrphoMed, Boston Pharmaceuticals, RedHill Biopharma Limited, Takeda, Cosmo Technologies, CinRx Pharma, Rottapharm, Synthetic Biologics, Biomica, Metacrine, MGC Pharma, Napo Pharmaceuticals, Novome Biotechnologies, Renexxion, Sentia Medical Sciences, Serentrix LLC, Vitality Biopharma, and others.

Dive deep into rich insights for drugs for Irritable Bowel Syndrome Pipeline, click here @ Irritable Bowel Syndrome Unmet Needs and Analyst Views-https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Irritable Bowel Syndrome Pipeline Report
• Coverage- Global
• Irritable Bowel Syndrome Companies- Arena Pharmaceuticals, 4D Pharma, OrphoMed, Boston Pharmaceuticals, RedHill Biopharma Limited, Takeda, Cosmo Technologies, CinRx Pharma, Rottapharm, Synthetic Biologics, Biomica, Metacrine, MGC Pharma, Napo Pharmaceuticals, Novome Biotechnologies, Renexxion, Sentia Medical Sciences, Serentrix LLC, Vitality Biopharma, and others.
• Irritable Bowel Syndrome Pipeline Therapies- Olorinab, Blautix, ORP-101, BOS-589, BEKINDA, Rifamycin controlled-release, CIN 103, Crofelemer, RQ-00310941, AAT 730, and others.
• Irritable Bowel Syndrome Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

Got Queries? Find out the related information on Irritable Bowel Syndrome Mergers and acquisitions, Irritable Bowel Syndrome Licensing Activities @ Irritable Bowel Syndrome Emerging Drugs, and Recent Trends-https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Irritable Bowel Syndrome Executive Summary
3. Irritable bowel syndrome: Overview
4. Irritable Bowel Syndrome Pipeline Therapeutics
5. Irritable Bowel Syndrome Therapeutic Assessment
6. Irritable bowel syndrome - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. ORP-101: OrphoMed
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Irritable bowel syndrome Key Companies
21. Irritable bowel syndrome Key Products
22. Irritable bowel syndrome- Unmet Needs
23. Irritable bowel syndrome- Market Drivers and Barriers
24. Irritable bowel syndrome- Future Perspectives and Conclusion
25. Irritable bowel syndrome Analyst Views
26. Irritable bowel syndrome Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

This release was published on openPR.